Cytokine signaling and resistance to CDK4/6 inhibitors in HR+HER2− breast cancer
While CDK4/6 inhibitors improved clinical outcomes in HR+HER2- metastatic breast cancer (MBC), resistance invariably occurs. The underlying molecular mechanisms are not actionable, leaving limited therapeutic options for progressing patients. Recent data highlight a role for IL-6 in the resistance o...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Portfolio
2025-10-01
|
| Saila: | npj Precision Oncology |
| Sarrera elektronikoa: | https://doi.org/10.1038/s41698-025-01108-z |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|